Health Care Equipment & Services

ResMed’s steady rise in the sleep‑disorder‑breathing device market is built on a robust global network, cloud‑connected technology, and a focus on data‑driven care, positioning the company to grow with aging populations and digital health trends.

Edwards Lifesciences price‑target upgrades reveal bullish consensus driven by FDA approvals, a strong pipeline, and a technical breakout—boosting investor confidence and patient outcomes.

ResMed shares rise modestly after‑hours amid healthcare sector momentum, driven by robust growth, FDA‑cleared CPAP devices, and AI‑powered respiratory innovations.

Edwards Lifesciences sees analyst upgrades, higher price targets, and a revised 2025 revenue outlook, boosting confidence in its cardiovascular device growth strategy.

Edwards Lifesciences sees a bright future: analysts raise price targets, 2025 revenue climbs, and a bold strategy drives growth in transcatheter valves and global expansion.

Siemens Healthineers stock swings as analysts weigh stake‑sale fears against strong AI‑driven diagnostics, high EBITDA margins, and a growing HealthSuite subscription model that could drive future growth.

UnitedHealth Group (UNH) sees rising call‑option volume, a $5 % revenue outlook lift, steady $4.18 dividend, and intensified NY regulatory scrutiny—what does this mean for investors?

McKesson’s steady conference appearance and unchanged stock show its entrenched role as North America’s top pharma distributor, proving resilience in a shifting healthcare supply chain.

Humana explores a partnership with Mark Cuban’s Cost‑Plus Drugs to offer direct‑to‑patient, transparent‑pricing mail‑order pharmacy services for Medicare members.

BD’s new insider sale, ChemoGLO partnership, and modular cell‑analyzer rollout boost safety, precision, and scalability in diagnostics.